Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOVA Iovance Biotherapeutics	$2.11 -20.1%	$2.22	$1.64 ▼ $12.51	$881.59M	0.88	26.31 million shs	43.40 million shs
MLYS Mineralys Therapeutics	$13.00 +1.0%	$14.25	$8.24 ▼ $18.38	$838.81M	-0.29	693,613 shs	502,001 shs
SLRN Acelyrin	$2.27	$2.27	$1.85 ▼ $7.10	$229.17M	1.07	1.29 million shs	N/A
URGN Urogen Pharma	$17.75 -4.5%	$14.05	$3.42 ▼ $21.01	$858.88M	1.12	1.34 million shs	1.18 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOVA Iovance Biotherapeutics	-20.08%	-21.27%	+6.03%	+20.57%	-71.21%
MLYS Mineralys Therapeutics	+1.01%	-4.83%	-9.53%	-11.26%	+15.25%
SLRN Acelyrin	0.00%	0.00%	0.00%	-3.81%	-54.05%
URGN Urogen Pharma	-4.52%	-8.51%	+28.53%	+71.50%	+22.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IOVA Iovance Biotherapeutics	4.6624 of 5 stars	4.2	1.0	0.0	4.2	2.9	4.2	1.3
MLYS Mineralys Therapeutics	2.1321 of 5 stars	3.4	1.0	0.0	0.0	1.8	4.2	0.0
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	4.604 of 5 stars	4.5	4.0	0.0	4.5	2.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IOVA Iovance Biotherapeutics	2.38	Hold	$11.90	463.98% Upside
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	148.08% Upside
SLRN Acelyrin	2.40	Hold	$9.60	322.91% Upside
URGN Urogen Pharma	3.00	Buy	$32.86	85.11% Upside

Current Analyst Ratings Breakdown

Latest SLRN, URGN, IOVA, and MLYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	IOVA Iovance Biotherapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$18.00 ➝ $14.00
8/8/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
8/5/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/23/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/15/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
7/8/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
7/7/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/17/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
6/16/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
6/13/2025	URGN Urogen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$16.00
6/13/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Buy	$31.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IOVA Iovance Biotherapeutics	$164.07M	4.29	N/A	N/A	$2.33 per share	0.91
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	$6.74 per share	N/A
URGN Urogen Pharma	$90.40M	9.07	N/A	N/A	($0.21) per share	-84.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-161.44%	-51.95%	-40.78%	N/A
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-71.15%	-65.71%	8/12/2025 (Estimated)
SLRN Acelyrin	-$381.64M	-$2.69	N/A	N/A	N/A	N/A	-44.12%	-39.02%	8/12/2025 (Estimated)
URGN Urogen Pharma	-$126.87M	-$3.18	N/A	N/A	N/A	-164.44%	-97,487.15%	-55.66%	N/A

Latest SLRN, URGN, IOVA, and MLYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MLYS Mineralys Therapeutics	-$0.78	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	SLRN Acelyrin	-$0.71	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	IOVA Iovance Biotherapeutics	-$0.29	-$0.33	-$0.04	-$0.33	$67.14 million	$59.95 million
8/7/2025	Q2 2025	URGN Urogen Pharma	-$0.85	-$1.05	-$0.20	-$1.05	$23.06 million	$24.22 million
5/14/2025	Q1 2025	SLRN Acelyrin	-$0.95	-$0.55	+$0.40	-$0.55	N/A	N/A
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/12/2025	Q1 2025	URGN Urogen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IOVA Iovance Biotherapeutics	N/A	4.18	3.64
MLYS Mineralys Therapeutics	N/A	26.48	26.48
SLRN Acelyrin	N/A	7.15	7.15
URGN Urogen Pharma	N/A	5.65	5.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IOVA Iovance Biotherapeutics	77.03%
MLYS Mineralys Therapeutics	84.46%
SLRN Acelyrin	87.31%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
IOVA Iovance Biotherapeutics	10.30%
MLYS Mineralys Therapeutics	25.56%
SLRN Acelyrin	13.60%
URGN Urogen Pharma	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	48.52 million	Optionable
SLRN Acelyrin	135	100.95 million	86.68 million	Optionable
URGN Urogen Pharma	200	46.20 million	44.03 million	Optionable

SLRN, URGN, IOVA, and MLYS Headlines

Recent News About These Companies

UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript

2 hours ago | seekingalpha.com

Urogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% on Disappointing Earnings

4 hours ago | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% Following Weak Earnings

August 8 at 11:22 AM | marketbeat.com

UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...

August 8 at 7:41 AM | finance.yahoo.com

UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI

August 8 at 2:30 AM | tipranks.com

UroGen (URGN) Q2 Revenue Rises 11%

August 7 at 12:52 AM | aol.comA

UroGen (URGN) Q2 Revenue Rises 11%

August 7 at 12:52 AM | aol.comA

UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat

August 7 at 12:52 AM | investing.com

UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat

August 7 at 12:52 AM | investing.com

Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft

August 7 at 2:45 PM | tipranks.com

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates

August 7 at 10:16 AM | zacks.com

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

August 7 at 8:00 AM | globenewswire.com

UroGen Pharma Q2 2025 Earnings Preview

August 6 at 6:14 PM | msn.com

D. Boral Capital Reaffirms Buy Rating for Urogen Pharma (NASDAQ:URGN)

August 6 at 9:20 AM | marketbeat.com

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade ...

August 6 at 5:42 AM | finance.yahoo.com

Urogen Pharma (NASDAQ:URGN) Sets New 1-Year High - Should You Buy?

August 5, 2025 | marketbeat.com

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

August 5, 2025 | globenewswire.com

Privium Fund Management B.V. Has $1.19 Million Stock Position in Urogen Pharma (NASDAQ:URGN)

August 3, 2025 | marketbeat.com

Jefferies Financial Group Inc. Lowers Holdings in Urogen Pharma (NASDAQ:URGN)

August 1, 2025 | marketbeat.com

Mark Schoenberg Sells 5,149 Shares of Urogen Pharma (NASDAQ:URGN) Stock

July 31, 2025 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) General Counsel Sells $143,971.08 in Stock

July 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
Why the American Eagle Stock Rally Isn't Just Speculation
By Gabriel Osorio-Mazilli | July 28, 2025
View Why the American Eagle Stock Rally Isn't Just Speculation
America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
This Drone Stock Is on Sale Despite Big Army Contract
By Jeffrey Neal Johnson | July 31, 2025
View This Drone Stock Is on Sale Despite Big Army Contract
3 Bullish Biotech Stocks With Explosive Growth Trends
By Chris Markoch | July 21, 2025
View 3 Bullish Biotech Stocks With Explosive Growth Trends

SLRN, URGN, IOVA, and MLYS Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

$2.11 -0.53 (-20.08%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.10 0.00 (-0.24%)

As of 08/8/2025 07:58 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Mineralys Therapeutics NASDAQ:MLYS

$13.00 +0.13 (+1.01%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$13.32 +0.32 (+2.50%)

As of 08/8/2025 05:46 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Acelyrin NASDAQ:SLRN

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Urogen Pharma NASDAQ:URGN

$17.75 -0.84 (-4.52%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$17.95 +0.20 (+1.15%)

As of 08/8/2025 07:29 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time